Kymera Therapeutics

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients Read More >

New Way, New Rules

Advancing targeted protein degradation to deliver next-generation medicines

Targeted Protein Degradation

The Future is Wide Open

Conventional medicines such as small molecule inhibitors and monoclonal antibodies address fewer than 20% of disease-causing proteins. Targeted Protein Degradation (TPD) is the gateway to the rest of the vast, unexplored proteome and a new way to develop highly targeted drug candidates for many intractable diseases.

Discover What Makes a Target a Good Candidate

By understanding the intricacies of the protein degradation process and applying our proprietary target ID capabilities, we identify high value targets likely to benefit from therapeutic intervention.

Pathway to Progress

Kymera’s vision is to build a platform that is disease agnostic and delivers the broadest possible impact. Since our founding in 2016, we have made significant progress in our research endeavors and built pre-clinical data packages to drive development of multiple drug candidate programs across disease areas.